Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03327883 · ClinicalTrials.gov registry record
Retrospective Review of FDG PET MRI Management of Patients With Muscle Invasive Bladder Cancer
A clinical trial, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- 15
- Enrollment target
NCT03327883: Completed study, sponsored by National Cancer Institute (NCI).
NCT03327883 is a clinical trial that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 15 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03327883 has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- 15 participants
- Enrollment target
Study Summary
Background: Bladder cancer is a common cancer in the U.S. Survival rates for metastatic bladder cancer have not gotten better for 15 years. Diagnosing and assessing the disease is important for treating it. The best way to tell what stage a cancer is in is computed tomography. This is also called CT. But it does not always give the best images of the bladder. Adding a test called positron emission tomography (PET) can help. Magnetic resonance imaging (MRI) is even better than CT for detecting bladder cancer. But it is not widely used. Some people with bladder cancer have already had MRI/PET and CT. Researchers want to study their records. They want to compare the different ways of assessing the disease. Objective: To evaluate the use of MRI/PET for diagnosing and treating metastatic bladder cancer. Eligibility: People 18 years and older who were in studies between 2013 and 2016 Design: Researchers will study existing records. There will be no active participants. The records will have no data that could identify the participants. Data will be stored on secure computers. No study participants will be contacted without approval from a review board.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2017-10-26 |
| Est. Completion | 2018-10-16 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03327883
The ClinicalTrials.gov registry entry for NCT03327883 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT03327883 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03327883 about?
NCT03327883 is a clinical study titled "Retrospective Review of FDG PET MRI Management of Patients With Muscle Invasive Bladder Cancer". Background: Bladder cancer is a common cancer in the U.S. Survival rates for metastatic bladder cancer have not gotten better for 15 years. Diagnosing and assessing the disease is important for treating it. The best way to tell what stage a cancer is in is computed tomography. This is also called C...
What is the current status of trial NCT03327883?
This trial is currently completed. The enrollment target is 15 participants. The study started on 2017-10-26. Estimated completion is 2018-10-16.
Who is sponsoring clinical trial NCT03327883?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.